Tema Etfs LLC Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Tema Etfs LLC acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 7,962 shares of the medical equipment provider’s stock, valued at approximately $712,000.

A number of other hedge funds have also made changes to their positions in LNTH. Assenagon Asset Management S.A. increased its holdings in shares of Lantheus by 52.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 25,936 shares of the medical equipment provider’s stock valued at $2,320,000 after acquiring an additional 8,959 shares during the last quarter. Park Avenue Securities LLC increased its holdings in shares of Lantheus by 26.4% in the 4th quarter. Park Avenue Securities LLC now owns 2,458 shares of the medical equipment provider’s stock valued at $220,000 after acquiring an additional 513 shares during the last quarter. Empirical Asset Management LLC purchased a new position in shares of Lantheus in the 4th quarter valued at about $323,000. Procyon Advisors LLC increased its holdings in shares of Lantheus by 11.1% in the 4th quarter. Procyon Advisors LLC now owns 3,613 shares of the medical equipment provider’s stock valued at $323,000 after acquiring an additional 361 shares during the last quarter. Finally, Shelton Wealth Management LLC grew its stake in Lantheus by 77.8% during the 4th quarter. Shelton Wealth Management LLC now owns 11,969 shares of the medical equipment provider’s stock worth $1,071,000 after buying an additional 5,237 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 1.8%

Shares of LNTH stock opened at $81.24 on Friday. The business’s 50 day moving average is $97.11 and its two-hundred day moving average is $93.20. Lantheus Holdings, Inc. has a twelve month low of $75.00 and a twelve month high of $126.89. The company has a market capitalization of $5.62 billion, a P/E ratio of 13.52 and a beta of 0.23.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $372.76 million during the quarter, compared to analysts’ expectations of $377.37 million. During the same quarter last year, the business posted $1.69 earnings per share. The company’s revenue for the quarter was up .8% compared to the same quarter last year. As a group, equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on LNTH shares. Truist Financial dropped their price target on Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. B. Riley dropped their price target on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Finally, StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lantheus presently has an average rating of “Buy” and an average target price of $132.67.

Insider Buying and Selling at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. This trade represents a 8.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This represents a 10.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is currently owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.